Unum Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014133)
◆英語タイトル:Unum Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014133
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Unum Therapeutics Inc (Unum) is a cancer cell therapy company that discovers, develops, and commercializes novel antibody-coupled cellular immunotherapies. The company uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology for discovering and developing new cellular immunotherapies for cancer. Its ACTR technology is combined with tumor-specific antibodies and directs an individual’s cytotoxic T-lymphocytes (CTLs) to activate the body’s own immune system to fight cancer. The company works in partnership with other biotechnology company to develop new combinations of ACTR T-cells and tumor targeting antibodies. Unum is headquartered in Cambridge, Massachusetts, the US.

Unum Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Unum Therapeutics Raises USD65 Million in Series B Financing 10
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 12
Licensing Agreements 13
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 13
Equity Offering 14
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 14
Unum Therapeutics Inc – Key Competitors 15
Unum Therapeutics Inc – Key Employees 16
Unum Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Research And Development 18
Apr 03, 2017: Unum Therapeutics to present new data on ACTR platform at AACR 2017 18
Corporate Communications 19
Feb 09, 2016: Unum Therapeutics Appoints Jorn Aldag, an Acclaimed Biotechnology Veteran and Gene Therapy Pioneer, to its Board of Directors 19
Product News 20
12/01/2016: Unum Therapeutics to Present on its Antibody-Coupled T-Cell Receptor (ACTR) Platform at the Upcoming 58th American Society of Hematology Annual Meeting 20
10/20/2016: Unum Therapeutics to Present on its Antibody-Coupled T-Cell Receptor (ACTR) Platform at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy 2016 Meeting 22
Product Approvals 23
Jun 20, 2016: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR087 in Patients with Relapsed/Refractory B-cell Lymphoma 23
Clinical Trials 24
Jun 19, 2017: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma 24
Other Significant Developments 25
Jan 26, 2016: Unum Therapeutics Moves to New Headquarters in Cambridge, MA as It Continues to Expand and Advance its Cellular Immunotherapy Pipeline 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Unum Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Unum Therapeutics Raises USD65 Million in Series B Financing 10
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 12
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 13
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 14
Unum Therapeutics Inc, Key Competitors 15
Unum Therapeutics Inc, Key Employees 16

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Unum Therapeutics Inc-製薬・医療分野:企業M&A・提携分析(Unum Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆